Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 13, 2025, to provide business updates and highlights from its clinical pipeline presented at the 43rd Annual J.P. Morgan Healthcare Conference. The filing includes preliminary, unaudited financial information for the fourth quarter and full year 2024, which is subject to finalization. Investors should note that the company anticipates an acquired in-process research and development (IPR&D) charge of approximately $14 million on a pre-tax basis for Q4 2024, primarily related to asset acquisitions. This charge is expected to reduce GAAP and non-GAAP net income per diluted share by approximately $0.11 for the quarter. The company has also incorporated by reference a press release and conference presentation, which are expected to contain further details on its pipeline and strategic updates. While this information is furnished to the SEC, it is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act unless expressly incorporated into a filing. Investors are advised to review the full details within the referenced exhibits for a comprehensive understanding of Regeneron's recent performance and future outlook.
Key Highlights
- 1Regeneron provided preliminary unaudited financial information for Q4 and FY 2024 at the J.P. Morgan Healthcare Conference.
- 2The company expects an acquired in-process R&D (IPR&D) charge of approximately $14 million (pre-tax) for Q4 2024, mainly due to asset acquisitions.
- 3This IPR&D charge is projected to reduce Q4 2024 diluted EPS (both GAAP and non-GAAP) by approximately $0.11.
- 4The filing incorporates by reference a press release and a conference presentation from January 13, 2025.
- 5The press release and presentation likely contain business updates and highlights from Regeneron's clinical pipeline.
- 6The information furnished in this 8-K is not considered 'filed' under Section 18 of the Exchange Act unless expressly incorporated into another filing.